Ghassan K. Abou-Alfa, MD

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

Closing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.

Ghassan Abou-Alfa, MD, Robert Lewandowski, MD, FSIR, and Amit Singal, MD discuss potential novel combination therapies including immune checkpoint inhibitors plus tyrosine kinase inhibitors plus local-regional therapeutic strategies.

Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.

Drs Abou-Alfa, Singal, and Lewandowski discuss use of immune checkpoint inhibitors and liver function.

The panel reviews the HIMALAYA and IMbrave-150 clinical trials of checkpoint inhibitor combination therapy strategies in advanced HCC.

A deeper dive on immune checkpoint inhibitors in HCC including review of the mechanisms of action of the IO agents.

A multidisciplinary panel discusses use of immune checkpoint inhibitors in patients with advanced HCC.

Drs Singal and Lewandowski review use of tyrosine kinase inhibitors, sorafenib and lenvatinib, and discuss trials that combined systemic therapy with chemoembolization.

Experts in hepatocellular carcinoma discuss treatment options for locally advanced disease.

Dr Singal reviews the Child-Pugh scoring system, then Dr Lewandowski discusses the importance of considering liver function as well as disease burden when selecting a treatment strategy.

The panel shares insight as to which patients might be candidates for curative therapies such as embolization techniques and liver transplant.

Ghassan Abou-Alfa, MD leads Robert Lewandowski, MD, FSIR, and Amit Singal, MD in a discussion of the main risk factors for hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, discusses the questions that remain with infigratinib in advanced cholangiocarcinoma with FGFR2 gene fusions/translocations.

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, discusses ways to optimize treatment selection for patients with hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the progress that has been made in the treatment of patients with hepatocellular carcinoma (HCC).

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).